The Latest Analyst Ratings for Sage Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have provided indifferent ratings for Sage Therapeutics (NASDAQ:SAGE), with no bullish or bearish positions. The average 12-month price target for SAGE is $22.25, with a high of $25.00 and a low of $21.00. This target has increased by 2.68% over the past month. Analyst ratings are opinions on stock performance based on research and are updated typically once a quarter.
December 12, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sage Therapeutics has received indifferent ratings from 4 analysts over the past 3 months, with an average price target of $22.25, which has seen a slight increase of 2.68% over the past month.
The indifferent ratings from analysts suggest that there is no strong consensus on the stock's short-term growth potential, which typically leads to a neutral impact on the stock price. The slight increase in the average price target may indicate a modest positive sentiment, but without strong bullish or bearish opinions, the impact is likely to be limited.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100